Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Novocure Announces the Presentation of New Data at the 19th Annual Society of Neuro-Oncology Meeting


News provided by

Novocure

11 Nov, 2014, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

- Interim analysis of the pivotal phase III trial of Tumor Treating Fields in newly diagnosed glioblastoma (EF-14) will be presented as a late-breaking oral presentation

- Data from ten clinical and preclinical abstracts on Tumor Treating Fields from leading academic institutions will also be presented at the meeting

ST. HELIER, Jersey, Nov. 11, 2014 /PRNewswire/ -- Novocure™, a commercial stage oncology company, announced today that the pre-specified interim analysis of the pivotal phase III EF-14 study, a prospective, multi-center trial of Tumor Treating Fields (TTFields) together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM), will be presented as a late breaking oral presentation at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16, in Miami, Florida. In addition to the EF-14 interim analysis presentation, an additional 10 preclinical and clinical abstracts from leading academic institutions describing the latest aspects of TTFields therapy will be presented at the meeting.

Details of the late breaking abstract oral presentation are as follows:

Date: Saturday, November 15, 2014
Venue:  Session 5B: Clinical Trials - Late Breaking Abstracts
Time: 11:40 - 12:00pm EST
Type: Oral Presentation

Interim Analysis of EF-14; Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Presenter:
Roger Stupp MD, Director, University Hospital Cancer Center, University of Zurich, Zurich, Switzerland

Details on the poster presentations are as follows:

Alternating Electric Fields Perturb the Localization of Cytokinetic Furrow Proteins and Cause Aberrant Mitotic Exit
Presenter:
Yang et al
Abstract Number: ET-68
Time: Poster session on Friday, November 14, 2014 7:30-9:30pm ET

Dexamethasone Interference with Alternating Electric Fields (TTFields) Therapy for Recurrent Glioblastoma
Presenter:
Eric T. Wong MD, Beth Israel Deaconess Medical Center, Boston, MA
Abstract Number: AT-61
Time: Poster session on Friday, November 14, 2014 7:30-9:30pm ET

Trifluoropromazine Enhances TTFields Treatment in vitro
Presenter:
Moshe Giladi PhD, Novocure Ltd. Haifa, Israel
Abstract Number: ET-47
Time: Poster session on Friday, November 14, 2014 7:30-9:30pm ET

An Updated Analysis of Patient Registry Data on NovoTTF-100A Alternating Electric Fields Therapy for Recurrent Glioblastoma
Presenter:
Eric T. Wong MD, Beth Israel Deaconess Medical Center, Boston, MA
Abstract Number: ED-38
Time: Poster session on Saturday, November 15, 2014 5:00-7:00pm ET

Early Japanese Experience with NovoTTF-100A System for Recurrent GBM
Presenter:
Nita et al
Abstract Number: NT-25
Time: Poster session on Saturday, November 15, 2014 5:00-7:00pm ET

Case of Glioblastoma Patient Treated with NovoTTF Therapy at Recurrence Degenerating to Sarcoma
Presenter:
Majd et al
Abstract Number: RM-05
Time: ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

EF-21: A phase II Randomized Study of TTFields Therapy Versus Supportive Care in Non-small Cell Lung Cancer (NSCLC) Patients with 1-5 Brain Metastases (BM) following Stereotactic Radio-surgery (SRS)
Presenter:
Uri Weinberg MD, Novocure Ltd, Haifa, Israel
Abstract Number: NT-37
Time: ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

Investigating the Mechanisms of Action of Tumor Treating Fields: A Computational Modeling Study
Presenter:
Wenger et al
Abstract Number: TM-16
Time: ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

Malignant Glioma with Primitive Neuroectodermal Components: Clinical and Pathologic Features of Five Cases
Presenter:
Turner et al
Abstract Number: CB-16
Time: ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

Pathology of Cases of Imaging Progression in Patients Diagnosed with Glioblastoma who have been Treated with the Novocure-TTF Device in the EF-14 trial
Presenter:
New et al
Abstract Number: NT-26
Time: ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

About Glioblastoma
Glioblastoma is the most common form of primary brain cancer with approximately 10,000 patients diagnosed each year in the United States.  Expected overall survival from initial diagnosis is reported to be approximately 15 months. The disease is known as recurrent glioblastoma when the tumor progresses or recurs after initial treatment.  Overall survival from the time of recurrence has been reported at 3-5 months without active treatment. 

About the NovoTTF-100A System
The NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that the NovoTTF-100A System slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A System creates a low intensity, alternating electric field within a tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. In patients with recurrent glioblastoma brain tumors, the system has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The NovoTTF-100A System has received marketing approval in the United States (U.S.) under the brand name Optune™ and is a CE Marked device cleared for sale in the European Union, Switzerland, Australia and Israel.

Approved Indication
The U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.  Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.novottftherapy.com/safety or by calling toll free 1-855-281-9301.

About Novocure
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure U.S. operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Media and Investor Contact:
Ashley Cordova, Novocure
acordova@novocure.com
+1-212-767-7558

Related Links

http://www.novocure.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.